Literature DB >> 10708416

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

C Y Huang1, S Butrapet, D J Pierro, G J Chang, A R Hunt, N Bhamarapravati, D J Gubler, R M Kinney.   

Abstract

We constructed chimeric dengue type 2/type 1 (DEN-2/DEN-1) viruses containing the nonstructural genes of DEN-2 16681 virus or its vaccine derivative, strain PDK-53, and the structural genes (encoding capsid protein, premembrane protein, and envelope glycoprotein) of DEN-1 16007 virus or its vaccine derivative, strain PDK-13. We previously reported that attenuation markers of DEN-2 PDK-53 virus were encoded by genetic loci located outside the structural gene region of the PDK-53 virus genome. Chimeric viruses containing the nonstructural genes of DEN-2 PDK-53 virus and the structural genes of the parental DEN-1 16007 virus retained the attenuation markers of small plaque size and temperature sensitivity in LLC-MK(2) cells, less efficient replication in C6/36 cells, and attenuation for mice. These chimeric viruses elicited higher mouse neutralizing antibody titers against DEN-1 virus than did the candidate DEN-1 PDK-13 vaccine virus or chimeric DEN-2/DEN-1 viruses containing the structural genes of the PDK-13 virus. Mutations in the envelope protein of DEN-1 PDK-13 virus affected in vitro phenotype and immunogenicity in mice. The current PDK-13 vaccine is the least efficient of the four Mahidol candidate DEN virus vaccines in human trials. The chimeric DEN-2/DEN-1 virus might be a potential DEN-1 virus vaccine candidate. This study indicated that the infectious clones derived from the candidate DEN-2 PDK-53 vaccine are promising attenuated vectors for development of chimeric flavivirus vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708416      PMCID: PMC111800          DOI: 10.1128/jvi.74.7.3020-3028.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Direct sequencing of large flavivirus PCR products for analysis of genome variation and molecular epidemiological investigations.

Authors:  J G Lewis; G J Chang; R S Lanciotti; D W Trent
Journal:  J Virol Methods       Date:  1992-07       Impact factor: 2.014

2.  Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

Authors:  A G Pletnev; M Bray; J Huggins; C J Lai
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

3.  Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti.

Authors:  M M Khin; N Jirakanjanakit; S Yoksan; N Bhamarapravati
Journal:  Am J Trop Med Hyg       Date:  1994-12       Impact factor: 2.345

4.  Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8- cytotoxic T-cell clones.

Authors:  P G Livingston; I Kurane; C J Lai; M Bray; F A Ennis
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

5.  Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome.

Authors:  A Cahour; A Pletnev; M Vazielle-Falcoz; L Rosen; C J Lai
Journal:  Virology       Date:  1995-02-20       Impact factor: 3.616

6.  The NS 3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity.

Authors:  G Wengler; G Wengler
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

7.  Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice.

Authors:  A G Pletnev; M Bray; C J Lai
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Mutagenesis of the yellow fever virus NS2B/3 cleavage site: determinants of cleavage site specificity and effects on polyprotein processing and viral replication.

Authors:  T J Chambers; A Nestorowicz; C M Rice
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine.

Authors:  T Dharakul; I Kurane; N Bhamarapravati; S Yoksan; D W Vaughn; C H Hoke; F A Ennis
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

10.  Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities.

Authors:  P G Livingston; I Kurane; L C Dai; Y Okamoto; C J Lai; R Men; S Karaki; M Takiguchi; F A Ennis
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

View more
  60 in total

1.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.

Authors:  Smita Jaiswal; Navin Khanna; S Swaminathan
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.

Authors:  Claire Y-H Huang; Shawn J Silengo; Melissa C Whiteman; Richard M Kinney
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 4.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

5.  MicroRNA reduction of neuronal West Nile virus replication attenuates and affords a protective immune response in mice.

Authors:  Terza Brostoff; Patricia A Pesavento; Christopher M Barker; Joan L Kenney; Elizabeth A Dietrich; Nisha K Duggal; Angela M Bosco-Lauth; Aaron C Brault
Journal:  Vaccine       Date:  2016-09-13       Impact factor: 3.641

6.  Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

Authors:  Alexander J McAuley; Maricela Torres; Jessica A Plante; Claire Y-H Huang; Dennis A Bente; David W C Beasley
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

7.  Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice.

Authors:  Whitney R Baldwin; Jill A Livengood; Holli A Giebler; Janae L Stovall; Karen L Boroughs; Stephanie Sonnberg; Kelly J Bohning; Elizabeth A Dietrich; Yee Tsuey Ong; Hoang K Danh; Hetal K Patel; Claire Y-H Huang; Hansi J Dean
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

8.  Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.

Authors:  Joseph E Blaney; James Speicher; Christopher T Hanson; Neeraj S Sathe; Stephen S Whitehead; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2008-06-13       Impact factor: 3.641

9.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

10.  Engineering RNA interference-based resistance to dengue virus type 2 in genetically modified Aedes aegypti.

Authors:  Alexander W E Franz; Irma Sanchez-Vargas; Zach N Adelman; Carol D Blair; Barry J Beaty; Anthony A James; Ken E Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.